Shares of Syndax Pharmaceuticals SNDX were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 0.00% year over year to ($0.44), which beat the estimate of ($0.49).
Revenue of $380,000 unchanged by 0.00% from the same period last year, which beat the estimate of $200,000.
Guidance
Syndax Sees Q1 2021 R&D Expenses $25M-$30M; Sees Total Operating Expenses $30M-$35M
Syndax Pharmaceuticals Sees FY 2021 R&D Expenses $90M-$100M; Sees FY 2021 Total Operating Expenses $110M-$120M
Conference Call Details
Date: Mar 08, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/wdaqmgg3
Recent Stock Performance
52-week high: $27.85
Company's 52-week low was at $6.88
Price action over last quarter: Up 22.96%
Company Overview
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
